AWM Investment Company Inc. Has $1.85 Million Stock Position in OncoCyte Co. (NASDAQ:OCX)

AWM Investment Company Inc. trimmed its position in shares of OncoCyte Co. (NASDAQ:OCX - Free Report) by 29.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 775,804 shares of the company's stock after selling 321,371 shares during the period. AWM Investment Company Inc. owned about 4.61% of OncoCyte worth $1,846,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OCX. Broadwood Capital Inc. boosted its stake in shares of OncoCyte by 26.7% during the 4th quarter. Broadwood Capital Inc. now owns 6,244,405 shares of the company's stock worth $14,862,000 after acquiring an additional 1,315,339 shares in the last quarter. Pura Vida Investments LLC lifted its holdings in OncoCyte by 32.1% in the 4th quarter. Pura Vida Investments LLC now owns 654,451 shares of the company's stock worth $1,558,000 after purchasing an additional 159,106 shares during the last quarter. Geode Capital Management LLC boosted its position in OncoCyte by 31.8% during the fourth quarter. Geode Capital Management LLC now owns 137,069 shares of the company's stock worth $326,000 after purchasing an additional 33,089 shares during the period. Two Sigma Securities LLC acquired a new position in OncoCyte during the fourth quarter valued at approximately $31,000. Finally, Ground Swell Capital LLC bought a new position in shares of OncoCyte in the fourth quarter valued at approximately $26,000. 55.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on OCX shares. Lake Street Capital raised their price target on OncoCyte from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Stephens reissued an "equal weight" rating and issued a $4.00 target price on shares of OncoCyte in a research note on Tuesday, March 25th. UBS Group reiterated a "buy" rating and set a $8.00 price objective on shares of OncoCyte in a research note on Wednesday. Wall Street Zen began coverage on shares of OncoCyte in a research note on Sunday, April 6th. They issued a "sell" rating for the company. Finally, Needham & Company LLC reiterated a "buy" rating and set a $4.25 price target on shares of OncoCyte in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $6.06.

OncoCyte Trading Down 2.0%

Shares of OCX traded down $0.07 during trading hours on Monday, hitting $3.37. 17,123 shares of the stock traded hands, compared to its average volume of 58,028. The business has a fifty day moving average of $3.00 and a 200-day moving average of $2.70. The firm has a market capitalization of $96.38 million, a PE ratio of -0.95 and a beta of 0.95. OncoCyte Co. has a 1-year low of $1.92 and a 1-year high of $4.75.

OncoCyte (NASDAQ:OCX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $2.14 million during the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. As a group, equities research analysts expect that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.